Literature DB >> 3009643

Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs.

L R Stanberry, D I Bernstein, S Kit, M G Myers.   

Abstract

The natural history of genital reinfection with herpes simplex virus type 2 (HSV-2) three weeks to one year after initial infection was explored by using a guinea pig model. Intravaginal reinoculation with HSV-2 of animals that had recovered from initial genital infection produced by wild-type or thymidine kinase-deficient HSV-2 produced asymptomatic genital reinfection characterized by high-titered replication of HSV-2 in the vaginal vault. Reinoculation did not result in acute neural infection, as was seen during initial genital herpes, and no evidence of latent infection by the rechallenge strain could be demonstrated. The frequency of recurrences appeared to be established by the initial infection because reinfection did not alter the pattern of recurrent genital herpes. The present study suggest that asymptomatic reinfection may produce a reservoir of communicable virus and that initial infection with a less virulent mutant of HSV-2 may provide protection against subsequent reexposure to wild-type HSV-2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009643     DOI: 10.1093/infdis/153.6.1055

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections.

Authors:  D I Bernstein; C J Harrison
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D.

Authors:  J Charles Whitbeck; Zhen-Yu Huang; Tina M Cairns; John R Gallagher; Huan Lou; Manuel Ponce-de-Leon; Robert B Belshe; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

3.  Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2.

Authors:  G N Milligan
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Long-term presence of virus-specific plasma cells in sensory ganglia and spinal cord following intravaginal inoculation of herpes simplex virus type 2.

Authors:  Gregg N Milligan; Michael G Meador; Chin-Fun Chu; Christal G Young; Talitha L Martin; Nigel Bourne
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Chin-Fun Chu; Michael G Meador; Christal G Young; Jane E Strasser; Nigel Bourne; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2007-10-24       Impact factor: 4.054

6.  A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Authors:  Ronald L Veselenak; Mark Shlapobersky; Richard B Pyles; Qun Wei; Sean M Sullivan; Nigel Bourne
Journal:  Vaccine       Date:  2012-10-04       Impact factor: 3.641

7.  Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653,180) as therapy for experimental recurrent genital herpes.

Authors:  N Bourne; F J Bravo; W T Ashton; L C Meurer; R L Tolman; J D Karkas; L R Stanberry
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

8.  Enhanced in vitro reactivation of latent herpes simplex virus from neural and peripheral tissues with hexamethylenebisacetamide.

Authors:  D I Bernstein; J C Kappes
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

9.  Virus-specific immune memory at peripheral sites of herpes simplex virus type 2 (HSV-2) infection in guinea pigs.

Authors:  Jingya Xia; Ronald L Veselenak; Summer R Gorder; Nigel Bourne; Gregg N Milligan
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.